Key points for investors:
- Q1 fiscal 2026 results: net revenue $13.9M (ADHD portfolio $13.2M). On an apples-to-apples basis (excluding prior-year one-time rebate), ADHD revenue grew ~10% year-over-year and sequentially. Adjusted EBITDA was negative $0.6M. Net income was $2.0M (benefitted from derivative warrant gains).
- EXXUA commercial launch is on track: initial product shipments to 3PL expected in December 2025, formal sales force launch meeting in January 2026, with early revenue expected in the March 2026 quarter and meaningful ramp in June 2026 and beyond. EXXUA will be integrated into Aytu’s RxConnect patient access platform.
- Commercial preparations for EXXUA: ~40-person sales force focused on psychiatry, finalized territory realignments (about one-third of territories altered), KOL engagement, promotional materials, payer assessment strategy prioritizing RxConnect-driven dispensing, and pricing positioned at or above other unique psychiatric treatments.
- Intellectual property and lifecycle: method-of-use patent extended to September 2030; management is pursuing additional lifecycle management opportunities to potentially extend exclusivity beyond 2030.
- ADHD franchise defenses: Teva’s authorized generic entry was permitted Sept 1 but had not launched as of the call; Aytu launched its own authorized generic of Adzenys on Sept 2, which has quickly captured meaningful share. RxConnect (dispensing ~85% of branded ADHD scripts) is a material moat against typical retail generic substitution.
- Financial posture and guidance: cash $32.6M at Sept 30, 2025. Baseline operating expense roughly $10M per quarter (cash OpEx ~$10.1M). Management expects an incremental ~$10M FY2026 investment for EXXUA (about $6M one-time spend concentrated in Dec and March quarters). Management’s all-in breakeven (including EXXUA spend) is ~ $17.3M net revenue per quarter (cash breakeven ~$16.6M). Prefunded warrants: 9.4M outstanding (in addition to 10.2M common), causing P&L volatility due to derivative liability accounting.
- Product risk items: small fluoride-containing product revenue (~$300k this quarter; ~$1.4M TTM infant drops). Company monitoring FDA communications on fluoride but currently has no direct FDA action.
- Supply and manufacturing: management reports adequate bulk supply and API availability to support an outsized ramp vs. base-case forecasts; EXXUA COGS/royalty structure: ~28% royalty (effective COGS ~31%), implying ~69% gross contribution margin.
Overall takeaway: Aytu delivered resilient ADHD revenues and is positioned for a potentially transformational product launch (EXXUA) that management believes can materially re-rate the company if launch execution, payer access and uptake meet expectations. Investors should monitor EXXUA manufacturing/shipments in December, the January sales kickoff, early coverage/dispensing data from RxConnect, and quarterly spend cadence and cash runway tied to expected EXXUA revenue ramp.
Sign In
Buy AYTU
